Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation ...

The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the pathogenetic role of eosinophils is fundamentally different between asthma ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today ...

Enzyme Replacement Therapy for Pompe Disease Market to Reach $350 Million by 2025, Driven by Expanding Clinical Applications The global enzyme replacement therapy (ERT) targeting Pompe disease market ...

News Published: March 2008 Genzyme and Isis strike megadeal George S. Mack Nature Biotechnology 26, 251–252 (2008) Cite this article ...

Genzyme continued to drive growth for Sanofi in the first quarter, helped along by the company’s vaccines unit, but diabetes drugs are still struggling. Net sales were €8,391 million, an ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

Abcuro has begun to add commercial muscle ahead of the anticipated launch of an inflammatory disease drug, appointing ex-Priovant Therapeutics executive Courtney Cupples to its C-suite to lead the ...

Recombinant human TSH (rhTSH; Thyrogen ®, Genzyme Corporation, Cambridge, MA) is obtained following transfection of microorganisms with genes encoding the human α and β subunits of TSH; rhTSH ...

Mark Joseph Enyedy currently works at BioMarin Pharmaceutical, Inc., as Independent Director from 2023, Charles River Laboratories International, Inc., as Independent Director from 2025, and ...